AR080207A1 - Aminotiazolonas como modulares de los receptores de estrogenos alfa - Google Patents
Aminotiazolonas como modulares de los receptores de estrogenos alfaInfo
- Publication number
- AR080207A1 AR080207A1 ARP110100488A ARP110100488A AR080207A1 AR 080207 A1 AR080207 A1 AR 080207A1 AR P110100488 A ARP110100488 A AR P110100488A AR P110100488 A ARP110100488 A AR P110100488A AR 080207 A1 AR080207 A1 AR 080207A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- substituted
- groups
- arthritis
- Prior art date
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 13
- 125000001475 halogen functional group Chemical group 0.000 abstract 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- -1 -C (O) N (R5) (R6) Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 206010003246 arthritis Diseases 0.000 abstract 2
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 208000002574 reactive arthritis Diseases 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 206010003267 Arthritis reactive Diseases 0.000 abstract 1
- 208000025940 Back injury Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010007710 Cartilage injury Diseases 0.000 abstract 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 abstract 1
- 208000005243 Chondrosarcoma Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000012514 Cumulative Trauma disease Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010027452 Metastases to bone Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 208000033464 Reiter syndrome Diseases 0.000 abstract 1
- 206010038584 Repetitive strain injury Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000022159 cartilage development Effects 0.000 abstract 1
- 208000002849 chondrocalcinosis Diseases 0.000 abstract 1
- 208000017568 chondrodysplasia Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000019439 energy homeostasis Effects 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 208000005368 osteomalacia Diseases 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000001223 septic arthritis Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composiciones, intermedios y derivados de éstos y para tratar una condicion que incluye, pero sin limitarse a, espondilitis anquilosante, arterioescrelosis, artritis (tales como, artritis reumatoide, artritis infecciosa, artritis infantil, artritis psoriática, artritis reactiva), enfermedades relacionadas con los huesos (que incluyen aquellas relacionadas con la formacion de los huesos), cáncer de mamas (que incluyen aquellos insensibles a! tratamiento antiestrogenos), trastornos cardiovasculares, enfermedades relacionadas con cartílagos (tales como lesion/pérdida de cartílago, degeneracion de cartílago y aquellas relacionadas con la formacion del cartílago), condrodisplasia, condrosarcoma, lesion cronica en la espalda, bronquitis cronica, enfermedad inflamatoria cronica de las vías respiratorias, enfermedad pulmonar obstructiva cronica, diabetes, trastornos de homeostasis de energía, gota, seudogota, trastornos lipídicos, síndrome metabolico, mieloma multiple, obesidad, osteoartritis, osteogenesis imperfecta, metástasis osea osteolítica, osteomalacia, osteoporosis, enfermedad de Paget, enfermedad periodontal, polimialgia reumática, síndrome de Reiter, lesion por esfuerzo repetitivo, hiperglicemia, nivel elevado de glucosa en sangre y resistencia a la insulina. Reivindicacion 1: Un compuesto de formula (1) en donde X es CH o N; R1 es alquilo C1-4, halo o alquilo -C(O)-C1-4; en donde el alquilo C1-4 podría estar sustituido con halo; R2 es halo, ciano, H, alquilo C1-4, alquenilo C1-4, alcoxi C1-4, -C(O)N(R5)(R6), o hidroxilo; en donde el alquilo C1-4 podría estar sustituido con halo; R3 es H, halo, -CN o alquilo C1-4; y R4 es heteroarilo o alquilo, cicloalquilo o heterociclilo C1-4; en donde el alquilo C1-4 podría estar sustituido con uno o cinco grupos, los grupos se seleccionan independientemente de halo, -OR5, cicloalquilo, -N(R5)(R6), -C(O)OR5, -C(O)N(R5)(R6), -SO2N(R5)(R6), alquilo O-C1-4-OR5, heterociclilo opcionalmente sustituido con halo, oxo o alquilo C1-4 y heteroarilo opcionalmente sustituido con alquilo C1-4; en donde el cicloalquilo podría estar sustituido con uno a tres grupos, los grupos se seleccionan independientemente de halo, -C(O)OR5 y alquilo C1-4; en donde el heterociclilo podría estar sustituido independientemente con uno a tres grupos, los grupos seleccionados independientemente de halo, alquilo C1-4, y -OR5, en donde el alquilo C1-4 podría estar sustituido con -OR5; en donde R5 y R6 son independientemente H o alquilo C1-4; o un isomero optico, enantiomero, diastereomero, isomero cis-trans, racemato o una sal farmacéuticamente aceptable de éstos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30518110P | 2010-02-17 | 2010-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080207A1 true AR080207A1 (es) | 2012-03-21 |
Family
ID=43927926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100488A AR080207A1 (es) | 2010-02-17 | 2011-02-17 | Aminotiazolonas como modulares de los receptores de estrogenos alfa |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8445690B2 (es) |
| EP (1) | EP2536717B1 (es) |
| JP (1) | JP2013519730A (es) |
| KR (1) | KR20130001242A (es) |
| CN (1) | CN102834392A (es) |
| AR (1) | AR080207A1 (es) |
| AU (1) | AU2011218190A1 (es) |
| CA (1) | CA2789757A1 (es) |
| MX (1) | MX2012009529A (es) |
| RU (1) | RU2012139463A (es) |
| TW (1) | TW201144303A (es) |
| UY (1) | UY33231A (es) |
| WO (1) | WO2011103134A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013051632A1 (ja) * | 2011-10-04 | 2013-04-11 | 武田薬品工業株式会社 | 含窒素縮合複素環化合物 |
| CN104302322A (zh) | 2012-03-26 | 2015-01-21 | 日本化学药品株式会社 | 骨·软组织中产生的巨细胞性肿瘤或软骨肉瘤的预防或治疗剂 |
| CN104119285B (zh) * | 2013-04-28 | 2016-06-29 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| EP3050573B1 (en) | 2013-09-25 | 2019-12-11 | Nippon Chemiphar Co., Ltd. | Zaltoprofen for preventing metastasis of giant cell tumor that occurs in bone or soft parts, metastasis of chondrosarcoma, or metastasis of osteosarcoma |
| US10183938B2 (en) | 2014-12-16 | 2019-01-22 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors |
| CN104610157A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一类环丙基酰肼和卤代苯类结构的gpr119激动剂及其用途 |
| JP2018516973A (ja) | 2015-06-10 | 2018-06-28 | フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | α７−ニコチン性アセチルコリン受容体のアゴニストとしてのアミノベンゾイソオキサゾール化合物 |
| EP3334740A4 (en) | 2015-08-12 | 2019-02-06 | Axovant Sciences GmbH | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217983A (en) * | 1992-03-27 | 1993-06-08 | Du Pont Merck Pharmaceutical Company | (N-benzyl) acetaldehyde bicyclic heterocycles useful as topical antiinflammatories |
| AU2381397A (en) * | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| AU5348098A (en) | 1996-12-17 | 1998-07-15 | Quadrant Holdings Cambridge Limited | Melanocortins |
| KR20070041560A (ko) | 2004-07-14 | 2007-04-18 | 얀센 파마슈티카 엔.브이. | 에스트로겐 관련 수용체-알파 매개 질병 치료를 위한아릴리덴 |
| US8148361B2 (en) * | 2006-11-10 | 2012-04-03 | Bristol-Myers Squibb Company | Kinase inhibitors |
| EP2132188B1 (en) * | 2007-03-07 | 2011-12-14 | Janssen Pharmaceutica N.V. | Substituted phenoxy n-alkylated thiazoledinedione as estrogen related receptor-alpha modulators |
| RU2492164C2 (ru) * | 2008-04-16 | 2013-09-10 | Каро Био Аб | Новые лиганды эстрогеновых рецепторов |
-
2011
- 2011-02-16 RU RU2012139463/04A patent/RU2012139463A/ru not_active Application Discontinuation
- 2011-02-16 AU AU2011218190A patent/AU2011218190A1/en not_active Abandoned
- 2011-02-16 MX MX2012009529A patent/MX2012009529A/es not_active Application Discontinuation
- 2011-02-16 US US13/028,284 patent/US8445690B2/en not_active Expired - Fee Related
- 2011-02-16 CA CA2789757A patent/CA2789757A1/en not_active Abandoned
- 2011-02-16 JP JP2012553982A patent/JP2013519730A/ja not_active Withdrawn
- 2011-02-16 EP EP11706982.3A patent/EP2536717B1/en active Active
- 2011-02-16 KR KR1020127023765A patent/KR20130001242A/ko not_active Withdrawn
- 2011-02-16 CN CN2011800193329A patent/CN102834392A/zh active Pending
- 2011-02-16 TW TW100105004A patent/TW201144303A/zh unknown
- 2011-02-16 WO PCT/US2011/025004 patent/WO2011103134A1/en not_active Ceased
- 2011-02-17 UY UY0001033231A patent/UY33231A/es unknown
- 2011-02-17 AR ARP110100488A patent/AR080207A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2789757A1 (en) | 2011-08-25 |
| TW201144303A (en) | 2011-12-16 |
| UY33231A (es) | 2011-08-31 |
| KR20130001242A (ko) | 2013-01-03 |
| JP2013519730A (ja) | 2013-05-30 |
| WO2011103134A1 (en) | 2011-08-25 |
| US20110200587A1 (en) | 2011-08-18 |
| AU2011218190A1 (en) | 2012-09-06 |
| RU2012139463A (ru) | 2014-03-27 |
| CN102834392A (zh) | 2012-12-19 |
| EP2536717B1 (en) | 2014-06-04 |
| MX2012009529A (es) | 2013-01-14 |
| EP2536717A1 (en) | 2012-12-26 |
| US8445690B2 (en) | 2013-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080207A1 (es) | Aminotiazolonas como modulares de los receptores de estrogenos alfa | |
| NI200900163A (es) | Tiazolidinedionas fenoxi sustituidos como estrógenos relacionados a los moduladores del receptor alfa. | |
| AR065656A1 (es) | Tiazolidindionas n-alquiladas fenoxi sustituidas como moduladoras del receptor alfa relacionado con estrogeno | |
| AR065657A1 (es) | DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS. | |
| AR080206A1 (es) | Aminotiazolonas como moduladores del receptor alfa relacionados con estrogeno | |
| EP2548858A4 (en) | METHOD FOR PRODUCING ETHYLENE GLYCOL FROM POLY-HYDROXIDE COMPOUNDS | |
| AR065876A1 (es) | Compuestos activos para 11 beta -hsd1 | |
| RU2016143333A (ru) | Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение | |
| PE20150350A1 (es) | Acidos 5-aminotetrahidroquinolin-2-carboxilicos novedosos y su uso | |
| AR078153A1 (es) | Compuestos y composiciones como moduladores de la actividad de tlr | |
| CO6531444A2 (es) | Métodos sintéticos para compuestos espiro-oxoindol | |
| AR089644A1 (es) | Compuestos tipo anilina utiles como intermediarios para preparar insecticidas | |
| UY33278A (es) | Pirimidinas sustituidas como antagonistas del receptor de la protaglandina d2 | |
| AR093042A1 (es) | Derivados de etinilo | |
| AR087470A1 (es) | Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen | |
| ECSP11011118A (es) | ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3 | |
| RU2017121460A (ru) | Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение | |
| PE20181319A1 (es) | Compuestos de isoindol | |
| AR099047A1 (es) | Derivados etinilo | |
| AR104863A1 (es) | Derivados imidazol | |
| UY33279A (es) | Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2 | |
| PE20150733A1 (es) | Derivados de etinilo como moduladores de la actividad del receptor mglur5 | |
| RU2012152800A (ru) | Гидроксиалкилбензилпиразолы и их применение для лечения гиперпролиферативных и ангиогенных заболеваний | |
| RU2015106013A (ru) | Соединения пиразолкарбоксамида, композиции и способы применения | |
| PE20150685A1 (es) | Pirimidinas de ariletinilo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |